Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Inhalation Powder in Lung Transplant Recipients
NCT05501574Phase 2Terminated
- Sponsor
- TFF Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in lung transplant rejection, sponsored by TFF Pharmaceuticals. Primary endpoints: Effect on renal function at 12 weeks, Incidence of treatment-emergent AEs, serious adverse events (SAEs), and withdrawals due to AEs at 12 weeks and 14 more. Started Apr 2023; status: terminated.
02
Drugs
tacrolimus
03
Conditions
lung transplant rejection
Beyond the preview
Go deeper on NCT05501574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501574.